Posted by Michael Wonder on 21 Apr 2022
Astellas announces reimbursement for Xospata (gilteritinib) in most provinces for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation
21 April 2022 - Having access to an additional treatment option offers hope for Canadian adult AML patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation.
Astellas Pharma Canada announces today on World AML Day, that Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Quebec, Saskatchewan, and the Non-Insured Health Benefits program have all reimbursed Xospata (gilteritinib) for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation as confirmed by a validated test.
